Kura Oncology Stock Current Valuation
| KURA Stock | USD 7.84 0.01 0.13% |
Valuation analysis of Kura Oncology helps investors to measure Kura Oncology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current year's Enterprise Value is expected to grow to about 892.3 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (3.36). Fundamental drivers impacting Kura Oncology's valuation include:
Overvalued
Today
Please note that Kura Oncology's price fluctuation is slightly risky at this time. Calculation of the real value of Kura Oncology is based on 3 months time horizon. Increasing Kura Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kura Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kura Stock. However, Kura Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.84 | Real 6.69 | Target 28.36 | Hype 7.84 | Naive 8.56 |
The real value of Kura Stock, also known as its intrinsic value, is the underlying worth of Kura Oncology Company, which is reflected in its stock price. It is based on Kura Oncology's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kura Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kura Oncology helps investors to forecast how Kura stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kura Oncology more accurately as focusing exclusively on Kura Oncology's fundamentals will not take into account other important factors: Kura Oncology Company Current Valuation Analysis
Kura Oncology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Kura Oncology Current Valuation | (79.3 M) |
Most of Kura Oncology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kura Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Kura Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Kura Oncology is extremely important. It helps to project a fair market value of Kura Stock properly, considering its historical fundamentals such as Current Valuation. Since Kura Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kura Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kura Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Kura Current Valuation Historical Pattern
Today, most investors in Kura Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kura Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Kura Oncology current valuation as a starting point in their analysis.
Kura Oncology Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Kura Oncology has a Current Valuation of (79.3 Million). This is 100.55% lower than that of the Biotechnology sector and 101.71% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.48% higher than that of the company.
Kura Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kura Oncology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kura Oncology could also be used in its relative valuation, which is a method of valuing Kura Oncology by comparing valuation metrics of similar companies.Kura Oncology is currently under evaluation in current valuation category among its peers.
Kura Oncology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kura Oncology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kura Oncology's managers, analysts, and investors.Environmental | Governance | Social |
Kura Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | (79.3 M) | ||||
| Shares Outstanding | 80.75 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 98.86 % | ||||
| Number Of Shares Shorted | 9.25 M | ||||
| Price To Earning | (9.03) X | ||||
| Price To Book | 1.53 X | ||||
| Price To Sales | 11.75 X | ||||
| Revenue | 53.88 M | ||||
| Gross Profit | (101.46 M) | ||||
| EBITDA | (169.5 M) | ||||
| Net Income | (173.98 M) | ||||
| Cash And Equivalents | 450.26 M | ||||
| Cash Per Share | 6.73 X | ||||
| Total Debt | 16.59 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 25.73 X | ||||
| Book Value Per Share | 5.29 X | ||||
| Cash Flow From Operations | 134.32 M | ||||
| Short Ratio | 5.40 X | ||||
| Earnings Per Share | (2.02) X | ||||
| Target Price | 26.69 | ||||
| Number Of Employees | 192 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 633.12 M | ||||
| Total Asset | 760.16 M | ||||
| Retained Earnings | (895.42 M) | ||||
| Working Capital | 666.12 M | ||||
| Current Asset | 86.87 M | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 760.16 M |
About Kura Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kura Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kura Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kura Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Kura Oncology Piotroski F Score and Kura Oncology Altman Z Score analysis. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.